Securing funding remains a critical challenge for emerging companies, particularly in the biotech, medical device, and surgical instrumentation sectors. While traditional capital sources—angel investors, family offices, high-net-worth individuals, and venture capital—each come with their strategies and nuances, a wide range of alternative funding options have emerged over the past five decades.
This program will explore these often overlooked or misunderstood sources of capital, including non-dilutive funding such as federal and state grants, venture studios and foundries, strategic partnerships, and other creative financing mechanisms.
